Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREATION: RAG-17 in SOD1-ALS Patients
NCT05903690Phase 1Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- May 2023
- Primary completion
- Jul 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of RAG-17 in amyotrophic lateral sclerosis (ALS), sponsored by Beijing Tiantan Hospital. Primary endpoint: Adverse events (AE) and serious adverse events (SAE) at 240 days. Started May 2023; status: completed.
02
Drugs
RAG-17
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05903690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903690.